Probiosimilarity Study: A Comprehensive Approach to Compare the Attributes of Marketed Probiotics Containing Bacillus clausii

Mathan Natarajan; Ragul Kessavane

doi:10.46798/ijam.2023.v25i02.4

Mathan Natarajan General Manager (Research & Development), R.S. No.55/1, 2 & 3, Whirlpool Road, Thiruvandarkoil, Puducherry- 605102, India.
Ragul Kessavane Executive Scientist (Research & Development), Allianz Biosciences Pvt Ltd, R.S. No.55/1, 2 & 3, Whirlpool Road, Thiruvandarkoil, Puducherry- 605102, India.

DOI: https://doi.org/10.46798/ijam.2023.v25i02.4

Keywords: Probiotics, Biosimilarity, Bacillus clausii, Enterogermina, antibiotic resistance

Abstract

Background: Probiotics are widely accepted functional foods for general well-being and a healthy lifestyle. A robust approach to evaluate the bio-similarities between marketed probiotics still needs to be developed. Aim: We aimed to define an approach that uses time-tested methods to evaluate pro-biosimilarity between different marketed probiotics. Methods: A total of five different Bacillus clausii formulations were compared with the international reference standard Enterogermina. The spore quantity and microbial purity of the samples were estimated. The antibiotic resistance strains in oral suspension samples were isolated and subjected to molecular characterization by 16S rRNA sequencing. The antibiotic susceptibility test was performed using commercially available antibiotics. The pH and transmittance of the samples were measured. Results: Bifilac Clausi had the highest, while Entromax had the lowest density of quality spores. None of the products had contaminant pathogenic microorganisms. Based on 16S rRNA sequencing, four strains from Bifilac Clausi and Enterogermina and one strain from other samples were identified. The identity of the strains from Bifilac Clausi matched those of Enterogermina. Bifilac Clausi and Enterogermina were resistant to the ten antibiotics tested. Conclusions: Among the different Indian brands of Bacillus clausii, only Bifilac Clausi was found to be a pro- biosimilar to the international reference standard, Enterogermina.

Author Biography

Ragul Kessavane, Executive Scientist (Research & Development), Allianz Biosciences Pvt Ltd, R.S. No.55/1, 2 & 3, Whirlpool Road, Thiruvandarkoil, Puducherry- 605102, India.

References

1. Amara,A.A.andShibl,A.,2015,―Roleofprobioticsinhealthimprovement,infectioncontroland disease treatment and management‖, Saudi Pharm J.,23(2), pp.107-14.
2. Kechagia, M., Basoulis, D., Konstantopoulou, S., Dimitriadi, D., Gyftopoulou, K., Skarmoutsou, N., et al.,2013, ―Health benefits of probiotics: a review‖, ISRN Nutr.,pp.481651.
3. Nagpal, R., Kumar, A., Kumar, M., Behare, P.V., Jain, S. and Yadav, H.,2012, ―Probiotics, their health benefits and applications for developing healthier foods: a review‖, FEMS Microbiol Lett., 334(1), pp.1- 15.
4. Kort,R.,Westerik,N.,MarielaSerrano,L.,Douillard,F.P.,Gottstein,W.,Mukisa,I.M.,etal.2015,―A novel consortium of Lactobacillus rhamnosus and Streptococcus thermophilus for increased access to functional fermented foods‖, Microb Cell Fact.,14(1), pp.195.
5. Merenstein, D. and Salminen, S., 2017, ―Probiotics and prebiotics‖, World Gastroenterology Organisation Global Guidelines.
6. Su,G.L.,Ko,C.W.,Bercik,P.,Falck-Ytter,Y.,Sultan,S.,Weizman,A.V.,etal.2020,―AGAclinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders‖,Gastroenterology, 159(2), pp.697-705.
7. McFarland, L.V., Evans, C.T., Goldstein EJC.,2018. ―Strain-specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis‖, Front Med (Lausanne)5, pp.124.
8. Szajewska, H., Canani, R.B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., et al. 2016, ―Probiotics for the prevention of antibiotic-associated diarrhea in children‖, J Pediatr Gastroenterol Nutr.,62(3), pp. 495-506.
9. Khatri, I., Tomar, R., Ganesan, K., Prasad, G.S. and Subramanian, S.,2017, ―Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii‖, Sci Rep., 7(1), pp. 371.
10. Cruchet,S.,Furnes,R.,Maruy,A.,Hebel,E.,Palacios,J.,Medina,F.,etal.2015,―Theuseofprobiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts‖,Paediatr Drugs., 17(3), pp.199-216.
11. Hill,C.,Guarner,F.,Reid,G.,Gibson,G.R.,Merenstein,D.J.,Pot,B.,etal.2014,‖Expertconsensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic‖, Nat Rev Gastroenterol Hepatol., 11(8), pp.506- 14.
12. Imperial, I.C.V.J. and Ilana, J.A.,2016, ―Addressing the antibiotic resistance problem with probiotics: reducing the risk of its double-edged sword effect‖, Front Microbiol.,7, pp.1983.
13. Ghelardi, E., Celandroni, F., Salvetti, S., Gueye, S.A.,Lupetti, A. and Senesi, S.,2015, ―Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore- based probiotic formulation‖ J ApplMicrobiol., 119(2), pp.552-9.
14. Thota, P., Thota, A., Medhi, B., Sidhu, S., Kumar, P., Selvan, V.K., et al. 2018, ―Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India‖,Perspect Clin Res., 9(1), pp.51-5.
15. Kumar, S., Stecher, G. and Tamura, K., 2016,―MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets‖, Mol BiolEvol., 33(7), pp.1870-4.
16. European Food Safety Authority (EFSA) EFSA. ―Technical guidance-Update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance‖. EFSA J. 2008, 6, pp.732.
17. Sharma, S., Arora, M. and Baldi, A.,2013, ―Probiotics in India: current status and future prospects‖, Pharm Aspire., 1, pp.1-12.
18. Patrone, V., Molinari, P. and Morelli, L.,2016, ―Microbiological and molecular characterization of commercially available probiotics containing Bacillus clausii from India and Pakistan‖, Int J Food Microbiol., 237, pp.92-7.
19. Gueimonde, M., Sánchez, B., G de Los Reyes-Gavilán, C. andMargolles, A.,2013, ―Antibiotic resistance in probiotic bacteria‖, Front Microbiol., 4, pp.202.
20. Ouwehand, A.C., Forssten, S., Hibberd, A.A., Lyra, A. and Stahl, B. 2016, ―Probiotic approach to prevent antibiotic resistance‖, Ann Med., 48(4), pp.246-55.